 |
|
|
| |
A 24-week phase 2a maintenance study of TMB-365/TMB-380 q8w in people with suppressed HIV-1 infection
|
| |
| |
Glasgow 2026 Nov 8-11
Lancet HIV publication Nov 2026
Download the PDF here
Download the PDF here
Safety, pharmacokinetics, and antiviral activity of a combination of TMB-365 and TMB-380 in people living with HIV suppressed with antiretroviral therapy in the USA: a phase 1b/2a, open-label, dose-escalation study
|
| |
|
|
|
|
|
